A Phase 3 interventional study of HIP2602 + HPP2602-2 and HPP2602-1 + HPP2602-2 in Erectile Dysfunction, sponsored by Hanmi Pharmaceutical Company Limited. Recruiting at 1 site in South Korea. Open to male participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Hanmi Pharmaceutical Company Limited · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Erectile Dysfunction with a site in Korea, Republic of — 3 open to participants now, 3 under way, 2 of them phase 3. Erectile Dysfunction · Korea, Republic of.
Among the 31 studies in Erectile Dysfunction with a site in Korea, Republic of, this one is the 5th largest by planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2026, is one of 8 in phase 3, and was the 31st registered.
702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.
Browse Erectile Dysfunction studies →3 of the 31 studies in Erectile Dysfunction with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Pharmicell Co., Ltd. · Sites in Korea, Republic of
Ages 19–80 · Men only
GL Pharm Tech Corporation · Sites in Korea, Republic of
Ages 19+ · Men only
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 19 Years to 75 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 225 is above the median of 70 across 551 interventional studies indexed under Erectile Dysfunction.
Median enrollment 104 across the 25 interventional studies, 54 across the 6 observational. Of the 22 that completed or were terminated, 2 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 31 have an industry lead sponsor. The 10 most frequent:
Hanmi Pharmaceutical Company Limited is the lead sponsor of 191 studies on the registry; 12 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
Hanmi Pharmaceutical Company Limited has 6 studies filed under Erectile Dysfunction — fewer than ten, so there is no comparison to draw.
2 of the studies in Erectile Dysfunction with a site in Korea, Republic of that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07859202Phase 3GL Pharm Tech CorporationThe Purpose of This Study is to Evaluate the Efficacy and Safety of W2505. | 2027-07 |
| NCT07899073Phase 3Hanmi Pharmaceutical Company LimitedA Study to Evaluate Efficacy and Safety of HIP2602 in Erectile Dysfunction Patients | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 31 studies in Erectile Dysfunction with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Multicenter, Randomized, Double-blind, Phase Ⅲ Study to Evaluate Efficacy and Safety of HIP2602 in Erectile Dysfunction Patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Visit 1 (screening)
Visit 2 (Randomization)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Daily administration, oral
Drug: HIP2602 + HPP2602-2
Daily administration, oral
Drug: HPP2602-1 + HPP2602-2
Daily administration, oral
Drug: HGP1201 + HPP2602-1
Test drug
Control drug
Active Comparator
Change of IIEF-EF domain score from baseline after 12 weeks
Time frame: baseline, 12 weeks
Change of IIEF-EF domain score from baseline after 6 weeks
Time frame: baseline, 6 weeks
Change of IIEF-OF domain score from baseline after 6, 12 weeks
Time frame: baseline, 6 weeks, 12 weeks
Change of IIEF-SD domain score from baseline after 6, 12 weeks
Time frame: baseline, 6 weeks, 12 weeks
Change of IIEF-IS domain score from baseline after 6, 12 weeks
Time frame: baseline, 6 weeks, 12 weeks
Change of IIEF-OS domain score from baseline after 6, 12 weeks
Time frame: baseline, 6 weeks, 12 weeks
Change of IIEF Question 3 score from baseline after 6, 12 weeks
Time frame: baseline, 6 weeks, 12 weeks
Change of IIEF Question 4 score from baseline after 6, 12 weeks
Time frame: baseline, 6 weeks, 12 weeks
The proportion or participants achieving IIEF-EF domain score ≥ 26 after 6, 12 weeks
Time frame: 6 weeks, 12 weeks
The proportion (%) of participants who responded "Yes" to Sexual Encounter Profile (SEP) Questions 1, 2, 3, 4, and 5 at Weeks 6 and 12 compared with baseline
Time frame: baseline, 6 weeks, 12 weeks
The proportion of participants who responded "Yes" to Global Assessment Question (GAQ) at Week 12
Time frame: 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Sep 2027, 11 months later.
Of 16 phase 3 interventional studies under Erectile Dysfunction, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 30. This study's planned 11 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hanmi Pharmaceutical Company Limited →